These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30352234)

  • 1. RASpecting the oncogene: New pathways to therapeutic advances.
    Stout MC; Campbell PM
    Biochem Pharmacol; 2018 Dec; 158():217-228. PubMed ID: 30352234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras proteins as therapeutic targets.
    Chakraborty A; Linnane E; Ross S
    Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Approaches to RAS Mutation.
    Scott AJ; Lieu CH; Messersmith WA
    Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers.
    Aguilar BJ; Zhou H; Lu Q
    Curr Med Chem; 2017; 24(32):3485-3507. PubMed ID: 28571533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in cancer drug discovery targeting RAS.
    Wilson CY; Tolias P
    Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology, pathology, and therapeutic targeting of RAS.
    Rhett JM; Khan I; O'Bryan JP
    Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
    Michael JV; Goldfinger LE
    Semin Cancer Biol; 2019 Feb; 54():121-130. PubMed ID: 29203271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RAS-Effector Interaction as a Drug Target.
    Keeton AB; Salter EA; Piazza GA
    Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic RAS: From Its Activation to Its Direct Targeting.
    Zaravinos A
    Crit Rev Oncog; 2017; 22(3-4):283-301. PubMed ID: 29604905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dragging ras back in the ring.
    Stephen AG; Esposito D; Bagni RK; McCormick F
    Cancer Cell; 2014 Mar; 25(3):272-81. PubMed ID: 24651010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the RAS oncogene.
    Takashima A; Faller DV
    Expert Opin Ther Targets; 2013 May; 17(5):507-31. PubMed ID: 23360111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Ras inhibition as an antitumor strategy.
    Marín-Ramos NI; Ortega-Gutiérrez S; López-Rodríguez ML
    Semin Cancer Biol; 2019 Feb; 54():91-100. PubMed ID: 29409706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras as a therapeutic target in hematologic malignancies.
    Alvarado Y; Giles FJ
    Expert Opin Emerg Drugs; 2007 May; 12(2):271-84. PubMed ID: 17604501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.